Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million on February 26, 2024. As for consideration, purchase price comprises, $8 million upfront, which is payable at closing in the form of $2 million and $6 million in ordinary shares, equating to approximately 0.82 million ordinary shares, $5 million performance-related milestone payments, payable in cash, that are subject to meeting milestone conditions within twelve months of closing, and a two-year revenue share based on actual revenue earned from existing customers of IsoTherapeutics total estimated cash payments $0.6 million. Transaction is subject to Closing of the customary conditions, including regulatory approvals.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.91 AUD | +0.20% | +9.55% | +47.92% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+47.92% | 3.21B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- TLX Stock
- News Telix Pharmaceuticals Limited
- Telix Pharmaceuticals Limited entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million.